Both regulators engage early with innovation, provided you ask the right way.
EMA offers scientific advice, protocol assistance and product-specific programmes. Orphan designation, PRIME eligibility, paediatric investigation plans and ATMP classification have distinct purposes and criteria. Biotechnology-derived biosimilars use the mandatory centralised route.
Kaiveo Medical helps Chinese biotech companies prepare agency questions, assess evidence gaps and plan global development through founder-led coordination. For drug-led combination products, the medicines pathway leads, with device-component requirements assessed as applicable. Specialist manufacturing and supply-chain needs are scoped with your team.
Challenges we solve
Scientific advice and protocol assistance strategy, briefing books, rehearsals and follow-up.
Orphan designation, PRIME eligibility, ATMP classification and paediatric-plan requirements assessed for the product and development stage.
Global study design, country and site feasibility, and start-up coordination with Regulatory Affairs for CTA/IND dossiers.
Assessment of comparability, applicable GMP and supply-chain requirements with your CMC and quality teams.
Regulatory and clinical due-diligence packages for European licensing conversations.
Early assessment of HTA and payer evidence questions to inform development planning.
How we support biotech clients
Regulatory Affairs
EU strategy, programme eligibility and agency interactions.
Clinical Research Management
Study planning and oversight for complex and advanced therapies.
Quality & Compliance
GMP for biologics and ATMPs, CDMO qualification.
Clinical & Medical Affairs
Expert-input and evidence planning in specialised therapy areas.
The same product, two regulators
Approval in one market does not carry over to the other. The relevance and sufficiency of existing evidence must be assessed for each intended route.
In Europe
- EMA scientific advice and protocol assistance
- PRIME eligibility, orphan designation and ATMP classification
- Paediatric investigation plans
- ATMP-specific GMP and comparability expectations
- Committee interactions: CHMP, CAT and COMP
- Assessment of trial legal-representation requirements
- Assessment of QP and QPPV requirements; separate appointments
In the United States
- Pre-IND and Type B / Type C meetings with FDA
- Fast Track, Breakthrough Therapy and RMAT designation
- Orphan drug designation and paediatric study plans
- Product-specific IND and NDA / BLA pathway assessment
- CBER interactions and INTERACT meetings
A typical biotech pathway
Product classification, programme eligibility and global evidence needs assessed.
Key CMC, non-clinical and clinical questions put to EMA with well-argued positions.
Study planning, site and CRO assessment, and start-up coordinated with the regulatory dossier work.
Marketing-application planning, agency interactions and launch-requirement assessment; outcomes depend on regulatory review.
